NYSEARCA:XBI SPDR S&P Biotech ETF (XBI) Price, Holdings, & News → Estee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI company (From Financial Markets Daily) (Ad) Free XBI Stock Alerts $93.84 +0.02 (+0.02%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$93.08▼$94.6050-Day Range$82.22▼$94.1252-Week Range$63.80▼$103.52Volume5.59 million shsAverage Volume10.98 million shsMarket Capitalization$7.15 billionAssets Under Management$7.17 billionDividend Yield0.02%Net Expense Ratio0.35% Stock AnalysisStock AnalysisChartHeadlinesHoldingsOwnershipRatingsStock AnalysisChartHeadlinesHoldingsOwnershipRatings Get SPDR S&P Biotech ETF alerts: Email Address About SPDR S&P Biotech ETF (NYSEARCA:XBI)SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.Read More XBI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XBI ETF News HeadlinesJune 4, 2024 | americanbankingnews.comTraders Purchase High Volume of Put Options on SPDR S&P Biotech ETF (NYSEARCA:XBI)May 24, 2024 | investorplace.comWhy the Rest of 2024 Could Be Good for Investing in Biotech StocksMay 14, 2024 | msn.comEvercore says biotech ‘winter is finally thawing’May 12, 2024 | msn.comCantor picks 14 undervalued biotech stocks worth a second lookApril 30, 2024 | msn.comStock Market Crash Warning: Don’t Get Caught Holding These 3 Biotech StocksApril 28, 2024 | nasdaq.comXBI June 7th Options Begin TradingApril 21, 2024 | seekingalpha.comSome Bubbles Are Starting To PopApril 20, 2024 | seekingalpha.comNovartis Looks To Get Back On Track With Q1 EarningsSee More Headlines Receive XBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerSSgA Fund NameSPDR S&P Biotech ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XBI Inception Date1/31/2006 Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio Webwww.spdrs.com Phone+1-866-7872257Fund Focus Asset ClassEquity BenchmarkS&P Biotech Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings137 Fund Statistics Assets Under Management$7.17 billion Average Daily Volume$8.87 million Discount/Premium0.02% Administrator, Advisor and Custodian AdministratorSSgA Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume116,970 Put Options90,784 Call Options26,186 Short Interest56,110,000 shs Miscellaneous Outstanding Shares76,220,000Beta1.11 Creation Unit50,000 Creation Fee$250.00 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Ad Porter & CompanyThe Key to this $10 Trillion Tech BoomPresident Biden has just approved $2.6 billion for this breakthrough technology… And it has nothing to do with artificial intelligence, cryptocurrency, or the blockchain.To get all the details of this new tech – click here now. SPDR S&P Biotech ETF ExpensesTypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.56%0.54%0.51%0.51%Other Expenses0.00%0.40%0.54%0.64%0.58%Total Expense0.35%0.72%0.70%0.74%0.70%Fee Waiver0.00%-0.53%-0.54%-0.68%-0.56%Net Expense0.35%0.60%0.60%0.58%0.58% SPDR S&P Biotech ETF (XBI) Holdings & ExposureTop 10 XBI HoldingsNovavax(NASDAQ:NVAX)Holding Weight: 3.53%Insmed(NASDAQ:INSM)Holding Weight: 2.22%Moderna(NASDAQ:MRNA)Holding Weight: 1.53%Twist Bioscience(NASDAQ:TWST)Holding Weight: 1.35%Revolution Medicines(NASDAQ:RVMD)Holding Weight: 1.33%PTC Therapeutics(NASDAQ:PTCT)Holding Weight: 1.32%Natera(NASDAQ:NTRA)Holding Weight: 1.29%Dyne Therapeutics(NASDAQ:DYN)Holding Weight: 1.28%BioCryst Pharmaceuticals(NASDAQ:BCRX)Holding Weight: 1.25%Agios Pharmaceuticals(NASDAQ:AGIO)Holding Weight: 1.24%XBI Sector ExposureXBI Industry ExposureFull Holdings Details Key ExecutivesJames E. Ross (Age 52)President, Trustee Peter A. Ambrosini (Age 69)Chief Compliance Officer Michael P. Riley (Age 44)Vice President Gary L. French (Age 64)Treasurer John W. Clark (Age 46)Assistant Treasurer Matthew W. Flaherty (Age 42)Assistant Treasurer Chad C. Hallett (Age 47)Assistant Treasurer of Street tracks series trust Mary Moran Zeven (Age 52)Secretary Scott M. Zoltowski (Age 44)Assistant Secretary Dave KellyIndependent TrusteeMore ExecutivesSimilar ETFsiShares Biotechnology ETFNASDAQ:IBBiShares U.S. Medical Devices ETFNYSEARCA:IHIiShares Global Healthcare ETFNYSEARCA:IXJiShares U.S. Healthcare ETFNYSEARCA:IYHFidelity MSCI Health Care Index ETFNYSEARCA:FHLCInstitutional OwnershipVerity Asset Management Inc.Bought 777 shares on 5/28/2024Ownership: 0.024%Farallon Capital Management LLCBought 500,000 shares on 5/24/2024Ownership: 0.000%Cetera Investment AdvisersBought 126,053 shares on 5/24/2024Ownership: 0.217%Cetera Advisors LLCBought 40,184 shares on 5/24/2024Ownership: 0.128%BigSur Wealth Management LLCBought 4,900 shares on 5/22/2024Ownership: 0.010%View All Institutional Transactions XBI ETF - Frequently Asked Questions How have XBI shares performed in 2024? SPDR S&P Biotech ETF's stock was trading at $89.29 on January 1st, 2024. Since then, XBI shares have increased by 5.1% and is now trading at $93.84. View the best growth stocks for 2024 here. What does XBI invest in? SPDR S&P Biotech ETF is a equity fund issued by SSgA. XBI focuses on health care investments and follows the S&P Biotech Index. The fund's investments total to approximately $7.17 billion assets under management. What stocks does SPDR S&P Biotech ETF hold? XBI invests in 137 holdings. Some of the stocks in their portfolio include Novavax (NVAX), Insmed (INSM), Moderna (MRNA), Twist Bioscience (TWST), Revolution Medicines (RVMD), PTC Therapeutics (PTCT), Natera (NTRA), Dyne Therapeutics (DYN), BioCryst Pharmaceuticals (BCRX) and Agios Pharmaceuticals (AGIO). What is the management fee for SPDR S&P Biotech ETF? SPDR S&P Biotech ETF's management fee is 0.35% and has no other recorded expenses or fee waivers. The net expense ratio for XBI is 0.35%. What other stocks do shareholders of SPDR S&P Biotech ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Biotech ETF investors own include Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Gilead Sciences (GILD), iShares Biotechnology ETF (IBB), Walt Disney (DIS), Micron Technology (MU), Cisco Systems (CSCO), AbbVie (ABBV) and Netflix (NFLX). Who are SPDR S&P Biotech ETF's major shareholders? SPDR S&P Biotech ETF's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Avoro Capital Advisors LLC (5.64%), Healthcare of Ontario Pension Plan Trust Fund (4.11%), Castle Hook Partners LP (2.20%), StemPoint Capital LP (0.00%), Jane Street Group LLC (1.26%) and Bessemer Group Inc. (1.21%). How do I buy shares of SPDR S&P Biotech ETF? Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEARCA:XBI) was last updated on 6/13/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more poten...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.